Bi‐Enzymatic Embolization Beads for Two‐Armed Enzyme‐Prodrug Therapy

Embolic beads, a successful tool for localized, site‐specific drug delivery, are engineered herein to contain the toolbox of enzyme‐prodrug therapy (EPT). EPT offers facile means to synthesize diverse drugs at their nominated concentrations; individually, in sequence, or in a combination. The authors investigate alginate beads as embolic bodies and screen alginate type and bead production parameters as factors to control activity of the immobilized enzymes. Engineered embolic bodies are armed with bi‐enzymatic EPT such that two enzymes perform biosynthesis of drugs with an independent control over each enzyme. Enzymatic synthesis of nitric oxide (NO) performed by embolic bodies is accomplished herein for the first time and is fine‐tuned such that flux of NO afforded by the beads matches that of healthy human endothelium. Ensuing vasodilation is illustrated ex vivo using rat mesenteric arteries. Independently, the production of SN‐38 is used to control the antiproliferative effects elicited by the beads. Bi‐enzymatic EPT engineered into embolic bodies thus affords opportunities for combination therapy and personalized treatment (adjusted combinations and concentrations of drugs) that go well beyond the state‐of‐the‐art of current embolic bodies and hold much promise for biomedical applications, specifically the treatment of hepatocellular carcinoma.

[1]  Uma Yasothan,et al.  Brentuximab vedotin , 2012, Nature Reviews Drug Discovery.

[2]  Organización Mundial de la Salud World health statistics 2017: monitoring health for the SDGs, Sustainable Development Goals , 2018 .

[3]  M. Stevens,et al.  Enzyme Prodrug Therapy Achieves Site-Specific, Personalized Physiological Responses to the Locally Produced Nitric Oxide , 2018, ACS applied materials & interfaces.

[4]  Jarkko Rautio,et al.  Prodrugs in medicinal chemistry and enzyme prodrug therapies , 2017, Advanced drug delivery reviews.

[5]  A. Zelikin,et al.  Substrate mediated enzyme prodrug therapy , 2017, Advanced drug delivery reviews.

[6]  M. J. Olesen,et al.  Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics , 2017, Advanced healthcare materials.

[7]  Junjie Fu,et al.  Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. , 2017, Journal of medicinal chemistry.

[8]  M. Hill,et al.  Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab , 2017, Advanced healthcare materials.

[9]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[10]  Molly M. Stevens,et al.  Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma , 2017, Advanced materials.

[11]  H. Ghandehari,et al.  Polymeric materials for embolic and chemoembolic applications. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[12]  S. McGuire World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[13]  Robert Langer,et al.  Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates , 2016, Nature Biotechnology.

[14]  Matthew A. Bochenek,et al.  Long term Glycemic Control Using Polymer Encapsulated, Human Stem-Cell Derived β-cells in Immune Competent mice , 2016, Nature Medicine.

[15]  Y. Weng,et al.  Nitric oxide producing coating mimicking endothelium function for multifunctional vascular stents. , 2015, Biomaterials.

[16]  Qingbo Xu,et al.  Enzyme-functionalized vascular grafts catalyze in-situ release of nitric oxide from exogenous NO prodrug. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[17]  D. Pinto dos Santos,et al.  Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma , 2015, BMC Cancer.

[18]  R. Salem,et al.  Transarterial approaches to primary and secondary hepatic malignancies , 2015, Nature Reviews Clinical Oncology.

[19]  Yong Wang,et al.  Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates , 2015, Nature materials.

[20]  A. Mendes,et al.  Enzyme Prodrug Therapy Engineered into Biomaterials , 2014 .

[21]  Brigitte Städler,et al.  Biocatalytic polymer coatings: on-demand drug synthesis and localized therapeutic effect under dynamic cell culture conditions. , 2014, Small.

[22]  A. Zelikin,et al.  Biocatalytic polymer thin films: optimization of the multilayered architecture towards in situ synthesis of anti-proliferative drugs. , 2014, Nanoscale.

[23]  Allan S. Myerson,et al.  Biocompatible Alginate Microgel Particles as Heteronucleants and Encapsulating Vehicles for Hydrophilic and Hydrophobic Drugs , 2014 .

[24]  David J Mooney,et al.  Macroscale delivery systems for molecular and cellular payloads. , 2013, Nature materials.

[25]  Asher Mullard Maturing antibody–drug conjugate pipeline hits 30 , 2013, Nature Reviews Drug Discovery.

[26]  C. Boyer,et al.  Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers. , 2013, Chemical communications.

[27]  A. Zelikin,et al.  Substrate Mediated Enzyme Prodrug Therapy , 2012, PloS one.

[28]  A. Zelikin,et al.  Engineering surface adhered poly(vinyl alcohol) physical hydrogels as enzymatic microreactors. , 2012, ACS applied materials & interfaces.

[29]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[30]  M. Schoenfisch,et al.  Nitric oxide release: part I. Macromolecular scaffolds. , 2012, Chemical Society reviews.

[31]  A. W. Carpenter,et al.  Nitric oxide release: part II. Therapeutic applications. , 2012, Chemical Society reviews.

[32]  G. Ameer,et al.  Polymer‐Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications , 2012, Advanced functional materials.

[33]  A. de Mel,et al.  Nitric oxide: a guardian for vascular grafts? , 2011, Chemical reviews.

[34]  Y. Weng,et al.  Immobilization of selenocystamine on TiO2 surfaces for in situ catalytic generation of nitric oxide and potential application in intravascular stents. , 2011, Biomaterials.

[35]  T. de Baère,et al.  Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. , 2010, Journal of vascular and interventional radiology : JVIR.

[36]  Ivan Donati,et al.  Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. , 2006, Biomacromolecules.

[37]  Henry Brem,et al.  Targeted therapy for brain tumours , 2004, Nature Reviews Drug Discovery.

[38]  L. Delbaere,et al.  Continuous spectrophotometric assay for beta-glucuronidase. , 2001, BioTechniques.

[39]  M. Mulvany,et al.  In vitro simultaneous measurements of relaxation and nitric oxide concentration in rat superior mesenteric artery , 1999, The Journal of physiology.

[40]  S Moncada,et al.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. , 1987, Biochemical and biophysical research communications.

[41]  K. Vorlop,et al.  Pore size and properties of spherical Ca-alginate biocatalysts , 1983, European journal of applied microbiology and biotechnology.